Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)

被引：7
|
作者：
Diefenbach, Catherine S. [1 ]
Jegede, Opeyemi [2 ]
Ansell, Stephen M. [3 ]
Steidl, Christian [4 ]
Natkunam, Yasodha [5 ,6 ]
Scott, David W. [7 ]
Mehta-Shah, Neha [8 ]
Amengual, Jennifer E. [9 ]
Forlenza, Christopher J. [10 ]
Cole, Peter D. [11 ]
Bartlett, Nancy L. [12 ]
David, Kevin A. [13 ]
Advani, Ranjana H. [14 ]
Ambinder, Richard F. [15 ]
Thomas, Sachdev [16 ]
Ibrahimi, Sami [17 ]
Kahl, Brad S. [18 ]
机构：
[1] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA
[2] CIMAC CIDC Network, Dept Data Sci, Boston, MA USA
[3] Mayo Clin, Div Hematol, Rochester, MN USA
[4] BC Canc, Ctr Lymphoid Canc, Vancouver, BC, Canada
[5] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA USA
[6] Stanford Univ, Med Ctr, Stanford, CA USA
[7] British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC, Canada
[8] Washington Univ, Div Oncol, Sch Med, St Louis, MO USA
[9] Columbia Univ, Div Hematol & Oncol, Lymphoma Program, Irving Med Ctr, New York, NY USA
[10] Mem Sloan Kettering Canc Ctr, West Harrison, NY USA
[11] NJ Rbt Wood Johnson Univ Hosp, Rutgers Ca Inst, New Brunswick, NJ USA
[12] Washington Univ, Siteman, Sch Med, St Louis, MO USA
[13] Rutgers State Univ, Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[14] Stanford Univ, Div Hematol & Oncol, Dept Med, Stanford, CA USA
[15] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[16] VA Cent Calif Hlth CARE Syst, Fresno, CA USA
[17] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA
[18] Washington Univ, Sch Med St Louis, St Louis, MO USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-184531
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
    Maruyama, Dai
    Terui, Yasuhito
    Yamamoto, Kazuhito
    Fukuhara, Noriko
    Choi, Ilseung
    Kuroda, Junya
    Ando, Kiyoshi
    Hattori, Akira
    Tobinai, Kensei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (11) : 1265 - 1273
  • [22] A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of a safety run-in-A trial of the ECOG-ACRIN Cancer Research Group (EA2174).
    Eads, Jennifer Rachel
    Weitz, Michelle
    Catalano, Paul J.
    Gibson, Michael K.
    Rajdev, Lakshmi
    Khullar, Onkar
    Lin, Steven H.
    Gatsonis, Constantine
    Wistuba, Ignacio Ivan
    Sanjeevaiah, Aravind
    Benson, Al Bowen
    Bahary, Nathan
    Spencer, Kristen Renee
    Saba, Nabil F.
    Hamilton, Stanley R.
    Staley, Charles A.
    Chakravarthy, Bapsi
    Fisher, George A.
    Wong, Terence Z.
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] 2-Year Follow-Up Results From the Phase 1-2 Study of Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 10 - 11
  • [24] Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma
    Chen, Robert
    Palmer, Joycelynne M.
    Martin, Peter
    Tsai, Nicole
    Kim, Young
    Chen, Bihong T.
    Popplewell, Leslie
    Siddiqi, Tanya
    Thomas, Sandra H.
    Mott, Michelle
    Sahebi, Firoozeh
    Armenian, Saro
    Leonard, John
    Nademanee, Auayporn
    Forman, Stephen J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (12) : 2136 - 2140
  • [25] Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO-4538-15): An interim analysis.
    Hatake, Kiyohiko
    Kinoshita, Tomohiro
    Fukuhara, Noriko
    Choi, Ilseung
    Taniwaki, Masafumi
    Ando, Kiyoshi
    Maruyama, Dai
    Terui, Yasuhito
    Higuchi, Yusuke
    Onishi, Yasushi
    Abe, Yasunobu
    Kobayashi, Tsutomu
    Shirasugi, Yukari
    Tobinai, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)
    Garcia-Sanz, Ramon
    Sureda, Anna
    Alonso-Alvarez, Sara
    Pilar Gonzalez, Ana
    Rodriguez, Antonia
    Salar, Antonio
    de la Cruz, Fatima
    Domingo, Eva
    Moreno, Miriam
    Lopez, Javier, Sr.
    Luis Pinana, Jose
    Rodriguez, Gabriela
    Canales, Miguel
    Manuel Gurierrez, Antonio
    Lopez-Guillermo, Armando
    Dolores Caballero, Maria
    Jimenez, Silvia
    Martinez, Carmen
    BLOOD, 2015, 126 (23)
  • [27] Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
    Morschhauser, Franck
    Flinn, Ian
    Advani, Ranjana H.
    Diefenbach, Catherine S.
    Kolibaba, Kathryn
    Press, Oliver W.
    Sehn, Laurie H.
    Chen, Andy I.
    Salles, Gilles
    Tilly, Herve
    Cheson, Bruce D.
    Assouline, Sarit
    Dreyling, Martin
    Hagenbeek, Anton
    Zinzani, Pier Luigi
    Yalamanchili, Sreeni
    Lu, Dan
    Jones, Cheryl
    Jones, Surai
    Chu, Yu-Waye
    Sharman, Jeff P.
    BLOOD, 2014, 124 (21)
  • [28] Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study
    Stamatoullas, Aspasia
    Ghesquieres, Herve
    Feugier, Pierre
    Andre, Marc
    Le Bras, Fabien
    Gac, Anne-Claire
    Borel, Cecile
    Gastinne, Thomas
    Quittet, Philippe
    Morschhauser, Franck
    Ribrag, Vincent
    Guidez, Stephanie
    Nicolas-Virelizier, Emmanuelle
    Berriolo-Riedinger, Alina
    Vander Borght, Thierry
    Edeline, Veronique
    Brice, Pauline
    LEUKEMIA & LYMPHOMA, 2022, 63 (13) : 3063 - 3071
  • [29] Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903)
    Kempin, Sanford
    Sun, Zhuoxin
    Kay, Neil E.
    Paietta, Elisabeth M.
    Mazza, Joseph J.
    Ketterling, Rhett P.
    Frankfurt, Olga
    Claxton, David F.
    Saltzman, Joel N.
    Srkalovic, Gordan
    Callander, Natalie S.
    Gross, Gerald
    Tallman, Martin S.
    ACTA HAEMATOLOGICA, 2019, 142 (04) : 224 - 232
  • [30] PRELIMINARY RESULTS OF A PHASE II RANDOMIZED STUDY (ROMULUS) OF POLATUZUMAB VEDOTIN OR PINATUZUMAB VEDOTIN PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL)
    Morschhauser, F.
    Flinn, I.
    Advani, R.
    Sehn, L.
    Kolibaba, K.
    Press, O.
    Salles, G.
    Diefenbach, C.
    Tilly, H.
    Assouline, S.
    Chen, A.
    Dreyling, M.
    Hagenbeek, A.
    Zinzani, P. L.
    Cheson, B. D.
    Yalamanchili, S.
    Lu, D.
    Chai, A.
    Chu, Y. W.
    Sharman, J.
    HAEMATOLOGICA, 2014, 99 : 525 - 525
12345